局部西罗莫司0.1%治疗皮肤微囊性淋巴管畸形(TOPICAL):多中心2期自身对照随机双盲溶媒对照试验方案
皮肤微囊性淋巴管畸形(CMLM)治疗困难,局部西罗莫司有个案报道有效。本方案为法国多中心2期自身对照随机双盲溶媒对照试验,计划纳入55例≥6岁原发CMLM患者,将病灶均分两区分别外用0.1%西罗莫司或溶媒12周,以第12周研究者盲法 Physician Global Assessment 评分作为主要终点比较疗效,并评估安全性、生活质量及全身吸收。
要点
- 局部西罗莫司0.1%可能成为CMLM非侵入性治疗选择。
- 采用自身对照随机双盲设计,主要终点为第12周Physician Global Assessment。
- 计划纳入55例≥6岁原发CMLM患者,病灶均分两区对照用药12周。
核心结论
- 若试验证实0.1%局部西罗莫司治疗CMLM有效且安全,可能改变该病管理并成为一线治疗。
研究设计与样本
- 法国盲法多中心2期自身对照随机对照试验,计划纳入55例≥6岁原发CMLM患者。
- 将CMLM均分两区随机分配至0.1%局部西罗莫司或溶媒,外用12周。
- 12周后患者/家长对剩余病灶全区域外用0.1%西罗莫司8周,第20周停药,第12个月评估长期疗效。
关键数值与推荐
- 主要终点为第12周研究者盲法Physician Global Assessment评分比较西罗莫司区与溶媒区CMLM改善。
- 次要终点包括独立专家基于标准化照片的疗效评估、生活质量影响、渗液/出血/红斑/厚度疗效及患者评估的全局与功能美观疗效。
- 第6、12、20周测西罗莫司全身吸收,CMLM≥900 cm2者在第16周加测。
临床怎么用
- 为CMLM患者提供潜在非侵入、耐受性好的治疗选择,待试验结果明确后0.1%西罗莫司乳膏可能成为一线治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cutaneous microcystic lymphatic malformations (CMLMs) are rare conditions in children and adults. They present as clusters of vesicles full of lymph and blood to various extents, inducing maceration, esthetic impairment, pain, and impaired quality of life. The treatment is challenging. Sirolimus is an inhibitor of mammalian target of rapamycin (mTOR) involved in angio-lymphangiogenesis. Topical sirolimus has recently been reported as effective in a few reports of patients with CMLMs. The objective is to compare the efficacy and safety of a 12-week application of 0.1% topical sirolimus versus topical vehicle in CMLMs in children and adults. METHODS: This French blinded multicenter within-person randomized controlled phase 2 trial aims to include 55 patients aged ≥ 6 years who have a primary CMLM. The CMLM will be divided into two equal areas that will be randomly allocated to 0.1% topical sirolimus or topical vehicle applied for 12 weeks. At the end of the 12-week period, the patient/parent will treat the whole area of CMLM with 0.1% topical sirolimus on remaining lesions, for eight more weeks. Patients will be seen at week 20 (treatment will be stopped) and at month 12 to evaluate long-term efficacy. The primary outcome will be improvement of the CMLM in the area treated with topical sirolimus compared to the area treated with topical vehicle by the investigator physician (blinded to the treatment) with the Physician Global Assessment score at week 12. Secondary outcomes will include: assessment of efficacy by independent experts on the basis of standardized photographs; impact on quality of life; efficacy for oozing, bleeding, erythema, and thickness evaluated by the investigators; and global efficacy as well as efficacy for functional and aesthetic impairment evaluated by the patient. Systemic passage of sirolimus will be measured at weeks 6, 12, and 20, and at week 16 for CMLMs ≥ 900 cm2. DISCUSSION: For patients with CMLMs, topical sirolimus could be a non-invasive and well-tolerated therapeutic option. If the trial demonstrates efficacy and safety of this treatment, this result will lead to a real change in the management of this condition, and 0.1% sirolimus cream would become the first-line treatment. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03972592. Registered on 3 June 2019. EU Clinical Trials Register EudraCT, 2018-001359-11.
引用
- Leducq S, Caille A, Barbarot S, et al. Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial. Trials. 2019. PMID: 31847908. doi:10.1186/s13063-019-3767-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。